Partnership and collaboration enable our ability to accelerate the global investigation of novel combination
treatments that address major unmet needs and have the potential to improve outcomes for people with cancer around
the world.
Strategic partners to advance global development and commercialization activities:
In May 2020, Arcus established a 10-year collaboration with Gilead that included a significant capital investment
and
equity stake by Gilead into Arcus. Under this collaboration, Gilead obtained time-limited exclusive option rights to
all Arcus clinical programs arising during the collaboration term*. Arcus and Gilead are co-developing four
investigational medicines, including domvanalimab (Arcus’s anti-TIGIT antibody), zimberelimab (Arcus’s
anti-PD-1 molecule), quemliclustat (Arcus’s CD73 inhibitor) and etrumadenant (Arcus’s adenosine receptor
antagonist). The collaboration was expanded in November 2021 and May 2023 to include research directed to two
targets for oncology and two targets for inflammatory diseases.
*Arcus Biosciences retains full rights to casdatifan.
Taiho has development and commercial rights in Japan and other countries in Asia, excluding China, for
domvanalimab,
zimberelimab, quemliclustat and etrumadenant. Taiho is operationalizing ongoing Phase 3 registrational studies
for
optioned molecules in Japan, including STAR-121, STAR-221 and PRISM-1.
Clinical collaborations to explore novel combinations
Arcus is interested in clinical collaborations that evaluate novel combinations of Arcus molecules with other
companies’ medicines or diagnostics to expand our understanding of important pathways and facilitate global
access to expedite development and commercialization.
Arcus Biosciences and AstraZeneca have two distinct clinical collaborations to evaluate novel combinations to
treat
cancer. These include:
-
eVOLVE-RCC02, a Phase 1b/3 study evaluating casdatifan, Arcus's investigational HIF-2a inhibitor,
with
volrustomig, AstraZeneca's investigational PD-1/CTLA-4 bispecific antibody, as a first-line treatment for patients
with metastatic clear cell renal cell
carcinoma
(ccRCC).
-
PACIFIC-8, a registrational Phase 3 clinical trial evaluating domvanalimab plus durvalumab (Imfinzi®) in
unresectable Stage 3 non-small cell lung cancer (NSCLC), where durvalumab is the standard of care.
AstraZeneca is the sponsor of and is operationalizing both studies.